Weekly shot aims to curb heavy drinking in overweight adults
NCT ID NCT06987513
Summary
This study is testing whether a weekly injection called pemvidutide can help adults who struggle with alcohol use disorder and are also overweight or obese. About 100 participants will receive either the real injection or a placebo (dummy shot) for 24 weeks to see if it reduces heavy drinking days. The main goal is to see if this treatment can help people drink less and improve their health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER (AUD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altimmune Clinical Study Site
Los Angeles, California, 90038, United States
-
Altimmune Clinical Study Site
Aurora, Colorado, 80045, United States
-
Altimmune Clinical Study Site
New Haven, Connecticut, 06511, United States
-
Altimmune Clinical Study Site
Fort Myers, Florida, 33912, United States
-
Altimmune Clinical Study Site
University Park, Florida, 34201, United States
-
Altimmune Clinical Study Site
North Canton, Ohio, 44720, United States
-
Altimmune Clinical Study Site
Tulsa, Oklahoma, 74136, United States
-
Altimmune Clinical Study Site
Philadelphia, Pennsylvania, 19104, United States
-
Altimmune Clinical Study Site
Providence, Rhode Island, 02923, United States
-
Altimmune Clinical Study Site
Charleston, South Carolina, 29425, United States
-
Altimmune Clinical Study Site
Charlottesville, Virginia, 22903, United States
-
Altimmune Clinical Study Site
Richmond, Virginia, 23298, United States
Conditions
Explore the condition pages connected to this study.